Selected Publications

Matthew Ho, Luca Paruzzo, Janna Minehart, Teja Voruganti, Pooja Devi Dan T. Vogl, Adam D. Cohen, Alfred L. Garfall, Adam J. Waxman, Shivani Kapur, Edward A. Stadtmauer, Sandra Susanibar Adaniya, Sarah Longworth: Nontuberculous mycobacterial infections following teclistamab in multiple myeloma. Haematologica February 2025.

Guido Ghilardi, Zainul S. Hasanali, Sandra P. Susanibar-Adaniya, Lena E. Winestone, Marco Ruella and Alfred L. Garfall: Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review. Journal for ImmunoTherapy of Cancer 13, January 2025.

Margaret Stalker, Alfred Garfall, Adam Cohen, Dan T. Vogl, Mia Djulbegovic, Sandra Susanibar-Adaniya, Edward Stadtmauer, Oxana Megherea, Adam J. Waxman: Safety and Efficacy of Teclistamab in Patients With Relapsed or Refractory AL Amyloidosis. European Journal of Hematology November 2024.

Omar Elghawy, Saarang Deshpande, Jonathan Sussman, Alfred Garfall, Adam Cohen, Shivani Kapur, Sandra Susanibar-Adaniya, Dan Vogl, Adam Waxman, Edward Stadtmauer: Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma. Bone Marrow Transplantation October 2024.

Zainul S Hasanali, Alfred L Garfall, Lisa Burzenski, Leonard D Shultz, Yan Tang, Siddhant Kadu, Neil C Sheppard, Derek Dopkin, Dan T Vogl, Adam D Cohen, Adam J Waxman, Sandra P Susanibar-Adaniya, Martin Carroll, Edward A Stadtmauer, David Allman: Human IL-6 fosters long-term engraftment of patient derived disease-driving myeloma cells in immunodeficient mice. JCI Insight 10: e177300, May 2024.

Ghilardi G, Fraietta JA, Gerson J, Caponetti GC, Paruzzo L, Harris JC, Susanibar S, Svoboda J, Chong EA, Nasta SD, Ugwuanyi O, Landsburg DJ, Fardella E, Waxman A, Patel V, Pajarillo R, Cohen AD, Levine BL, Stadtmauer EA, Frey NV, Vogl DT, Barta SK, Van Deerlin V, Morrissette JJD, Porter DL, Garfall AL, Schuster SJ, June CH, and Ruella M. : "T-cell Lymphoma and Secondary Malignancy Risk After Commercial Chimeric Antigen Receptor T-cell Immunotherapy: the Penn Experience" Nature Medicine January 2024 Notes: 2024, In press.

Xinhe Shan, Edward A. Stadtmauer, Sandra Susanibar-Adaniya: Real-Word Analysis of Clinical Characteristics and Outcomes Among Elderly Patients with Multiple Myeloma. American Society of Hematology. 65th Annual Meeting. Poster 3766, December 2023.

Zainul S. Hasanali, Beatrice Razzo, Sandra P. Susanibar-Adaniya, Alfred L. Garfall, Edward A. Stadtmauer, Adam D. Cohen.: Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma. Hematology/Oncology Clinics of North America Dec 2023.

Xinhe Shan, Qi Long, Alfred L. Garfall & Sandra P. Susanibar-Adaniya: High SOX2 expression is associated with poor survival in patients with newly diagnosed multiple myeloma. Blood Cancer Journal 13(1): 86, May 2023.

Sandra Susanibar-Adaniya, MD, MS: Low-affinity bispecific antibody produces high response rates in advanced multiple myeloma. Haelio. Hemonc today. April 2023.